Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.
Kim WesterdijkS D KrensN SteeghsW T A van der GraafE T T L TjwaH WestdorpI M E DesarN P van ErpPublished in: Cancer chemotherapy and pharmacology (2023)
Our study did not demonstrate a clear relationship between pazopanib exposure and the occurrence of pazopanib-induced liver toxicity. Half of the patients were able to safely continue or restart pazopanib treatment after liver toxicity and received the same dose as prior to drug withdrawal. Successful interventions to address pazopanib-induced toxicity in the clinic led to an algorithm for the management of pazopanib-induced liver toxicity.
Keyphrases
- high glucose
- end stage renal disease
- diabetic rats
- oxidative stress
- chronic kidney disease
- ejection fraction
- drug induced
- newly diagnosed
- healthcare
- prognostic factors
- machine learning
- physical activity
- stem cells
- emergency department
- palliative care
- electronic health record
- single cell
- quality improvement
- pain management
- young adults
- health insurance
- chronic pain
- patient reported
- adverse drug
- papillary thyroid
- data analysis